The BNT162b2 KP.2 vaccine effectively prevents severe COVID-19 outcomes, including hospitalizations and ED or UC visits.

Much of the message's information was misleading about a real variant of the virus that causes COVID-19.

bDepartment of Infectious Diseases and Unit of Post-COVID Huddinge, Karolinska University Hospital, Stockholm, Sweden cDepartment of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden ...

A major health challenge resulting from the COVID-19 pandemic is the manifestation of post-acute sequelae of SARS-CoV-2 (PASC). PASC (or long COVID) is a collective term used for clinical symptoms, ...

Department of Biomedical Sciences, Graduate School, Korea University, Seoul 02707, Republic of Korea BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, ...

A multi-institutional study led by researchers at the University of Alabama at Birmingham and the University of North Carolina at Chapel Hill has revealed a previously underappreciated mechanism by ...

The global pandemic may be over, but SARS-CoV-2 continues to infect people around the world. Indeed, the United States has recorded roughly 750 deaths from COVID-19 over the past month. Now, an siRNA ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...

Approximately 15 to 20 million Americans who have acquired COVID-19 experience persistent symptoms lasting over 3 months (long-COVID). Respiratory symptoms of long-COVID include breathlessness, ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the ...